Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBlue Cross Blue Shield KS Casgevy Coverage Update …
    Ask Trek AI about this page
    Currentblue cross blue shield - kansasPolicy N/A

    Casgevy (exagamglogene autotemcel) Medical Drug Criteria

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, eligibility, and coverage conditions for a single-dose autologous gene therapy (Casgevy) for patients with sickle cell disease or transfusion-dependent beta thalassemia under BCBSKS.

    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyCasgevy (exagamglogene autotemcel) Medical Drug Criteria
    Policy CodePolicy N/A
    Change TypeMaterial revisions to authorization length, clinical thresholds, and coding
    Effective DateAug 1, 2024
    Last ReviewDec 26, 2025
    Next Review DateDec 26, 2025
    Key ActionSubmit required medical records (chart notes) supporting diagnosis, step therapy, and genetic/mutational testing with the prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    Length of authorization changed from 'may not' to 'will not' be renewed; coverage limited to one treatment course (one dose).

    Requirement that patient has not had a prior HSCT and for patients under 18, no known suitable 10/10 HLA matched related donor willing to participate in allogeneic HSCT.

    Sickle cell disease criteria updated to require uncontrolled disease despite hydroxyurea OR crizanlizumab (or intolerance) or need for repeat transfusions; VOC threshold changed to two or more events in the previous year.

    HCPCS code J3392 (exagamglogene autotemcel) added effective 01/01/2025 and J3590 removed.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1treatment course authorized (single dose)
    >=12minimum patient age for coverage
    3 x 10^6minimum recommended dose
    J3392HCPCS code (effective 01/01/2025)
    >=100 mL/kg/yrtransfusion-dependence threshold

    Coverage Criteria for Casgevy (exagamglogene autotemcel)

    inv-01: Initial Therapy — General and administrative criteria

    Covered when ALL of the following are met

    General eligibility

    • Concomitant therapy restrictions: No iron chelators for at least 7 days prior to myeloablative conditioning and for 6 months post-treatment for myelosuppressive iron chelators (e.g., deferiprone) OR 3 months post-treatment for non-myelosuppressive iron chelators; disease-modifying agents (e.g., hydroxyurea, crizanlizumab) withheld for at least 8 weeks prior to mobilization and conditioning.
    ref
    title

    inv-02: Initial Therapy — Sickle Cell Disease

    AND for Sickle Cell Disease patients, ALL of the following must be met

    Sickle cell diagnostic and severity criteria: Confirmed diagnosis of sickle cell disease with genotype βS/βS, βS/β0, or βS/β+ (other genotypes may be considered case-by-case) by hemoglobin assay or identification of biallelic HBB pathogenic variants with at least one p.Glu6Val; patient has uncontrolled disease despite hydroxyurea OR crizanlizumab at any point in the past OR has experienced intolerance OR has required repeat transfusions to treat symptomatic disease and/or reduce stroke risk; severe symptomatic disease demonstrated by one or more of the following: TRJV >2.5 m/s; history of overt stroke; acute chest syndrome in the prior 2 years; OR two or more vaso-occlusive events/crises in the previous year (VOE/VOC defined as events requiring medical facility evaluation resulting in diagnosis and interventions such as opioid therapy, NSAIDs, or RBC transfusion); patient will be transfused prior to apheresis to a total hemoglobin ≤11 g/dL and HbS <30% and transfused at least 8 weeks prior to initiation of myeloablative conditioning; patient will not receive G-CSF for mobilization of HSCs.

    inv-03: Initial Therapy — Beta Thalassemia

    AND for Beta Thalassemia patients, ALL of the following must be met

    Beta thalassemia diagnostic and severity criteria: Documented homozygous or compound heterozygous beta thalassemia confirmed by HBB sequence showing biallelic pathogenic variants OR compatible laboratory/morphology and hemoglobin analysis consistent with severe beta thalassemia; transfusion-dependent disease defined as a history of transfusions of at least 100 mL/kg/year or ≥10 units/year of packed red blood cells in the 2 years preceding therapy; patient will be transfused prior to apheresis to a total hemoglobin ≥11 g/dL for 60 days prior to myeloablative conditioning; exclusion for severely elevated cardiac iron (cardiac T2* < 10 msec) or left ventricular ejection fraction <45% or advanced liver disease (AST/ALT >3x ULN, direct bilirubin >2.5x ULN, or biopsy showing bridging fibrosis/cirrhosis).

    inv-04: Administration timing

    AND procedural timing requirements

    Product timing and conditioning: Myeloablative conditioning should not begin until Casgevy and back-up cell collection are received; Casgevy must be administered between 48 hours and 7 days after the last dose of myeloablative conditioning; consider prophylaxis for hepatic veno-occlusive disease/sinusoidal obstruction syndrome prior to busulfan conditioning.

    Exclusions: Patients who have received prior gene therapies (for example, Lyfgenia® [lovotibeglogene autotemcel] or Zynteglo® [betibeglogene autotemcel]) are excluded from standard authorization for Casgevy. For Beta Thalassemia patients, exclusion criteria additionally include severely elevated cardiac iron (cardiac T2* < 10 msec), left ventricular ejection fraction < 45%, or evidence of advanced liver disease (AST or ALT > 3× ULN, direct bilirubin > 2.5× ULN, or biopsy showing bridging fibrosis or cirrhosis).

    Requests for additional doses or repeat courses beyond the single authorized treatment course are not covered. Coverage will be provided for one treatment course (1 dose of Casgevy) and will not be renewed.

    Coding and Product Identification

    Covered HCPCS CodesHCPCSCovered
    J3392Injection, exagamglogene autotemcel, per treatment; 1 billable unit = 1 treatment (Effective 01/01/2025)
    NDCNDC
    51167-0290-xxCasgevy containing a minimum of 3.0 × 10^6 CD34+ cells/kg of body weight, in one or more vials packaged in carton(s)
    inv-09: Minimum CD34+ cells/kg
    Minimum CD34+ cells/kg3 × 10^6 CD34+ cells/kg
    Dose presentationSingle intravenous dose in one or more vials to achieve patient-specific dose; administer all vials
    Patient verification prior to infusionConfirm patient's identity matches unique identifiers on Casgevy vial(s); do not infuse if labels do not match

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior Authorization / Documentation Required

    Prior authorization is required. Submit all relevant medical records/chart notes documenting diagnosis, prior therapies, transfusion history, and clinical markers supporting medical necessity. Failure to submit required medical records may result in denial of the prior authorization request.

    • Submission of medical records (chart notes) related to the medical necessity criteria is REQUIRED on all requests for authorizations.
    • Provide documentation related to diagnosis, step therapy, genetic/mutational testing, and transfusion history via direct upload through the PA web portal or by fax.
    Denial Risk

    Failure to Submit Required Records — Denial Risk

    Failure to submit the required records (e.g., documentation of prior therapies, transfusion dependence, genotype confirmation, and pre-collection infectious disease screening) may result in administrative denial or delay. Ensure records include evidence of prior use or intolerance of hydroxyurea or crizanlizumab (for sickle cell) or documentation of transfusion dependence (for beta thalassemia).

    Key Definitions and Thresholds

    inv-16: Minimum recommended dose
    Minimum recommended dose3 × 10^6 CD34+ cells/kg (minimum per dose)
    Administration window after conditioningMust be administered between 48 hours and 7 days after the last dose of myeloablative conditioning
    Vial handlingCasgevy supplied in one or more vials to achieve the patient-specific dose; administer all vials and confirm vial/patient identity before infusion
    inv-17: Transfusion-dependent beta thalassemia definition
    Transfusion-dependence definitionHistory of transfusions of at least 100 mL/kg/year or ≥10 units/year of packed red blood cells in the 2 years preceding therapy
    Pre-apheresis transfusion goalPatient will be transfused prior to apheresis to a total hemoglobin ≥11 g/dL for 60 days prior to myeloablative conditioning

    Background — Therapy Description

    Casgevy is an autologous, single-dose, ex vivo CRISPR-based gene-editing therapy administered as a CD34+ cell suspension for patients with sickle cell disease or transfusion-dependent beta thalassemia. Candidate patients must meet general safety and screening requirements prior to leukapheresis (including age ≥ 12 years, screening negative for HBV, HCV, and HIV-1/2, and no history of hypersensitivity to DMSO or dextran 40). Product handling requires confirmation of vial-to-patient identity prior to infusion, and conditioning/mobilization timing and concomitant therapy restrictions must be observed as specified in the clinical criteria.

    Policy Summary
    Payerblue cross blue shield - kansas
    PolicyCasgevy (exagamglogene autotemcel) Medical Drug Criteria
    Policy CodePolicy N/A
    Change TypeMaterial revisions to authorization length, clinical thresholds, and coding
    Effective DateAug 1, 2024
    Last ReviewDec 26, 2025
    Next Review DateDec 26, 2025
    Key ActionSubmit required medical records (chart notes) supporting diagnosis, step therapy, and genetic/mutational testing with the prior authorization request.
    SourceLink
    On This Page
    Coverage Criteria for Casgevy (exagamglogene autotemcel)Coding and Product IdentificationProvider Requirements and Prior AuthorizationKey Definitions and ThresholdsBackground — Therapy Description
    • Evidence of prior therapies: hydroxyurea or crizanlizumab trial OR documentation of intolerance or need for repeat transfusions (sickle cell).
    • Evidence of transfusion dependence: ≥100 mL/kg/year or ≥10 units/year pRBCs in the 2 years preceding therapy (beta thalassemia).
    • Pre-collection screening: HBV, HCV, and HIV-1/2 test results.
    Billing Rule

    Billing and Product Identification

    Billing must use HCPCS code J3392 for exagamglogene autotemcel. Confirm patient identity matches vial labeling prior to infusion; do not infuse if patient-specific vial label does not match the intended patient.

    • HCPCS: J3392 - Injection, exagamglogene autotemcel, per treatment; 1 billable unit = 1 treatment (Effective 01/01/2025).
    • Casgevy is provided as a single-dose autologous infusion — administer all vials to achieve the patient-specific dose.
    • Before infusion, confirm the patient's identity matches the unique patient identifiers on the Casgevy vial(s). Do not infuse if labels do not match.
    Documentation Required

    Required Prior Therapies / Disease Status (Documentation)

    Documentation of required prior therapies and disease status must be provided with the PA request. For sickle cell disease, include genotype confirmation and evidence of uncontrolled disease despite hydroxyurea or crizanlizumab, or documentation of transfusion use/intolerance. For beta thalassemia, include HBB sequencing or hematologic/hemoglobin analysis and documentation of transfusion dependence.

    • Sickle cell: genotype (βS/βS, βS/β0, βS/β+) confirmation by hemoglobin assay or molecular testing; documentation of prior hydroxyurea or crizanlizumab use or intolerance, or repeat transfusions.
    • Beta thalassemia: HBB sequence gene analysis showing biallelic pathogenic variants OR hemoglobin analysis consistent with severe disease; documentation of transfusion dependence (≥100 mL/kg/year or ≥10 units/year).
    • Note mobilization requirements: Sickle cell mobilization with plerixafor only; Beta thalassemia mobilization with plerixafor + G-CSF.
    Documentation Required

    Provider Actions — Submission Requirements

    Providers must ensure all specified documentation is included at time of submission to avoid administrative denials or delays in treatment authorization.

    • Include diagnosis, prior therapy history, transfusion records, genotype/testing results, infectious disease screening, and any relevant supportive care measures.
    • Provide documentation via the PA web portal upload or fax as instructed.
    Eligibility confirmatory testingDiagnosis confirmed by HBB sequence showing biallelic pathogenic variants OR compatible labs/morphology and hemoglobin analysis